TIZIANA LIFE SCIENCES LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.681 USD | +7.24% |
|
+6.41% | +21.61% |
Presentation Operator MessageOperator (Operator)Greetings, and welcome to the Tiziana Life Sci...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohnâs and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +21.61% | 68.31M | |
| +33.37% | 50.85B | |
| +1.55% | 42.82B | |
| +49.28% | 42.03B | |
| -4.22% | 29.55B | |
| +11.57% | 26.11B | |
| -21.00% | 19.13B | |
| +7.36% | 13.05B | |
| +28.30% | 12.16B | |
| +23.80% | 12.08B |
- Stock Market
- Equities
- TLSA Stock
- News Tiziana Life Sciences Ltd
- Transcript : Tiziana Life Sciences PLC - Special Call